For research use only. Not for therapeutic Use.
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation[1].
Basiliximab specifically inhibits T lymphocyte proliferation by binding to the IL-2Rα[1].
Basiliximab binds only to activated lymphocytes and macrophages/monocytes[3].
Basiliximab does not affect resting T lymphocytes that do not express IL-2Rα[3].
Basiliximab (CHI 621) (0.07 mg/rat; i.v.; once) decreases total placental natural killer cells in reduced uterine perfusion pressure (RUPP) rats[2].
| Catalog Number | I042969 |
| CAS Number | 179045-86-4 |
| Purity | ≥95% |
| Reference | [1]. McKeage K, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. BioDrugs. 2010 Feb 1;24(1):55-76. [2]. Cunningham M W, et al. The Role of Interleukin‐2 (IL‐2) in Natural Killer Cell (NK) Activation and Hypertension in a Preclinical Rat Model of Preeclampsia. The FASEB Journal, 2018, 32: 911.1-911.1. [3]. Chapman TM, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35. |
